Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus

Int J Cardiol. 2007 Nov 30;122(3):e36-8. doi: 10.1016/j.ijcard.2007.07.057.


This study was designed to investigate whether the serum concentration of the carboxy-terminal propeptide of procollagen type I (PIP), a marker of myocardial fibrosis, is related to changes of the ventricular filling dynamics in patients with early type 2 diabetes mellitus (T2DM). The T2DM group had lower mitral and tricuspid E/A ratios than the control group. Serum PIP was higher in patients with T2DM than in controls (131.1+/-45.6 vs. 109.3+/-32.5 ng/mL, p=0.039). A-Ar, an estimate of passive diastolic function, was inversely related to serum PIP levels in T2DM (r=-0.42, p=0.03). These results show a relation between LV diastolic function and serum PIP levels in early T2DM.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Biomarkers / blood
  • Blood Pressure / physiology
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / diagnosis
  • Humans
  • Peptide Fragments / blood*
  • Procollagen / blood*
  • Ventricular Dysfunction, Left / blood*
  • Ventricular Dysfunction, Left / complications
  • Ventricular Dysfunction, Left / diagnosis


  • Biomarkers
  • Peptide Fragments
  • Procollagen
  • procollagen type I carboxy terminal peptide